Brugarolas, James

Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex

Brugarolas, J., Lei, K., Hurley, R. L., Manning, B. D., Reiling, J. H., Hafen, E., Witters, L. A., Ellisen, L. W., & Kaelin, W. G. (2004) · Genes & Development

PI3K/AKT/mTOR signaling in cancerCancer, Hypoxia, and Metabolism

Cited by 1,384

Radiation-induced cell cycle arrest compromised by p21 deficiency

Brugarolas, J., Chandrasekaran, C., Gordon, J. I., Beach, D., Jacks, T., & Hannon, G. J. (1995) · Nature

Cancer-related Molecular PathwaysDNA Repair Mechanisms

Cited by 1,242

mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways

Majumder, P. K., Febbo, P. G., Bikoff, R., Berger, R., Xue, Q., McMahon, L. M., Manola, J., Brugarolas, J., McDonnell, T. J., Golub, T. R., et al. (2004) · Nature Medicine

PI3K/AKT/mTOR signaling in cancerCancer, Hypoxia, and Metabolism

Cited by 964

Targeting renal cell carcinoma with a HIF-2 antagonist

Chen, W., Hill, H., Christie, A., Kim, M. S., Holloman, E., Pavia-Jimenez, A., Homayoun, F., Ma, Y., Patel, N., Yell, P., et al. (2016) · Nature

Cancer, Hypoxia, and MetabolismRenal cell carcinoma treatment

Cited by 709

TSC2 regulates VEGF through mTOR-dependent and -independent pathways

Brugarolas, J. B., Vazquez, F., Reddy, A., Sellers, W. R., & Kaelin, W. G. (2003) · Cancer Cell

Tuberous Sclerosis Complex ResearchPI3K/AKT/mTOR signaling in cancer

Cited by 528

Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma

Courtney, K. D., Infante, J. R., Lam, E. T., Figlin, R. A., Rini, B. I., Brugarolas, J., Zojwalla, N. J., Lowe, A. M., Wang, K., Wallace, E. M., et al. (2018) · Journal of Clinical Oncology

Renal cell carcinoma treatmentCancer, Hypoxia, and Metabolism

Cited by 393

Biological Mechanisms and Clinical Significance of BAP1 Mutations in Human Cancer

Carbone, M., Harbour, J. W., Brugarolas, J., Bononi, A., Pagano, I., Dey, A., Krausz, T., Pass, H. I., Yang, H., & Gaudino, G. (2020) · Cancer Discovery

Chromatin Remodeling and CancerOcular Oncology and Treatments

Cited by 287

De novo and salvage purine synthesis pathways across tissues and tumors

Tran, D. H., Kim, D., Kesavan, R., Brown, H., Dey, T., Soflaee, M. H., Vu, H. S., Tasdogan, A., Guo, J., Bezwada, D., et al. (2024) · Cell

Biochemical and Molecular ResearchAdenosine and Purinergic Signaling

Cited by 213

HIF-2 complex dissociation, target inhibition, and acquired resistance with PT2385, a first-in-class HIF-2 inhibitor, in patients with clear cell renal cell carcinoma

Courtney, K. D., Ma, Y., Diaz de Leon, A., Christie, A., Xie, Z., Woolford, L., Singla, N., Joyce, A., Hill, H., Madhuranthakam, A. J., et al. (2020) · Clinical Cancer Research

Cancer, Hypoxia, and MetabolismRenal cell carcinoma treatment

Cited by 188

Immune-related adverse events are associated with improved outcomes in ICI-treated renal cell carcinoma patients.

Elias, R., Yan, F., Singla, N., Levonyack, N., Formella, J., Christie, A., Kapur, P., Bowman, A. I., Hammers, H. J., Hannan, R., et al. (2019) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersRenal cell carcinoma treatment

Cited by 48

A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma

Brugarolas, J., Obara, G., Beckermann, K. E., Rini, B., Lam, E. T., Hamilton, J., Schluep, T., Yi, M., Wong, S., Mao, Z. L., et al. (2024) · Clinical Cancer Research

Renal cell carcinoma treatmentCancer, Hypoxia, and Metabolism

Cited by 25

A phase I dose escalation trial of PT2385, a first-in-class oral HIF-2a inhibitor, in patients with advanced clear cell renal cell carcinoma.

Courtney, K. D., Infante, J. R., Lam, E. T., Figlin, R. A., Rini, B. I., Brugarolas, J., Zojwalla, N. J., Wang, K., Wallace, E., Josey, J. A., et al. (2016) · Journal of Clinical Oncology

Renal cell carcinoma treatmentCancer, Hypoxia, and Metabolism

Cited by 7